Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Don’t Let Corn Rootworm Steal Your Yield: Bayer Launches The Watch 2025
From Bayer
Via Business Wire
News headline image
AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)
From Bayer
Via Business Wire
News headline image
Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma
From Bayer
Via Business Wire
News headline image
Guru Ramamurthy Appointed as New CFO for Bayer’s Crop Science Division
From Bayer
Via Business Wire
News headline image
Agricultural Community Applauds Signing of New North Dakota Bill
From Bayer
Via Business Wire
News headline image
Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community
From Bayer
Via Business Wire
News headline image
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors
From Bayer
Via Business Wire
News headline image
Bayer announces filing of petition to U.S. Supreme Court for review of Durnell Roundup™ case
From Bayer
Via Business Wire
News headline image
Comprehensive Review of More Than 400 Studies Conducted Over 30 Years:
From Bayer
Via Business Wire
News headline image
ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes
From Bayer
Via Business Wire
News headline image
Dr. Mike Graham Appointed as New Head of R&D for Bayer’s Crop Science Division
From Bayer
Via Business Wire
News headline image
U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
From Bayer
Via Business Wire
News headline image
Bayer Introduces Vyconic™ Soybeans, a Groundbreaking Advance in Weed Management, at Commodity Classic 2025
From Bayer
Via Business Wire
News headline image
Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025:
From Bayer
Via Business Wire
News headline image
Bayer® Aspirin Continues Longstanding Commitment to Heart Health Education, Encouraging Americans to “See Their Risks”
From Bayer
Via Business Wire
News headline image
New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer Unveils Latest Data from Prostate Cancer Portfolio at 2025 ASCO GU Cancers Symposium
From Bayer
Via Business Wire
News headline image
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
From Bayer
Via Business Wire
News headline image
New U.S. Survey Conducted On Behalf Of One A Day® by Bayer Highlights Four in Five GenZ Women Feel Societal Pressures Impact Their New Year’s Resolutions
From Bayer
Via Business Wire
News headline image
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
From Bayer
Via Business Wire
News headline image
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
From Bayer
Via Business Wire
News headline image
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
From Bayer
Via Business Wire
News headline image
Elinzanetant Meets All Primary and Secondary Endpoints in Phase III Study OASIS 4 for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Breast Cancer Treatments
From Bayer
Via Business Wire
News headline image
Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia
From Bayer
Via Business Wire
News headline image
Bayer Partners with America’s Grow-A-Row to Aid in the Fight Against Hunger in New Jersey
From Bayer
Via Business Wire
News headline image
Bayer Showcases Growing Radiology Portfolio at RSNA 2024
From Bayer
Via Business Wire
News headline image
Bayer Announces ‘Project Enhanced S3’ to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects
From Bayer
Via Business Wire
News headline image
U.S. FDA Accepts Supplemental New Drug Application for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.